Literature DB >> 6211308

Defective handling of mannan by monocytes in patients with chronic mucocutaneous candidiasis resulting in a specific cellular unresponsiveness.

A Fischer, L Pichat, M Audinot, C Griscelli.   

Abstract

Carbohydrate antigens from Candida albicans, essentially mannan, have previously been shown to persist in the serum of some patients with chronic mucocutaneous candidiasis, and to be able to inhibit specifically the candida antigen-induced proliferation of control lymphocytes. Lymphocytes from three out of six patients were shown to be hypersensitive to mannan inhibition. These data were explained by the demonstration of an apparently selective impairment of radiolabelled mannan handling by two patients' monocytes following a normal uptake. This defect was observed both in active and remission phases of the infection suggesting an intrinsic defect of patients' monocytes. In experiments performed with control lymphocytes, it was shown that mannan exerted its suppressive effect by interfering with candida antigen presentation by adherent cells to autologous T lymphocytes. Furthermore, mannan neither was cytotoxic nor induced suppressor T cells. Altogether, these data suggest that the in vivo persistance of mannan, in some patients, is secondary to a primary macrophage dysfunction leading to impairment of specific cellular immune responsiveness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6211308      PMCID: PMC1536428     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

Review 1.  Analysis of human Candida precipitins by quantitative immunoelectrophoresis: a model for analysis of complex microbial antigen-antibody systems.

Authors:  N H Axelsen
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

2.  Deposition of complement components in the cutaneous lesions of chronic mucocutaneous candidiasis.

Authors:  P G Sohnle; M M Frank; C H Kirkpatrick
Journal:  Clin Immunol Immunopathol       Date:  1976-05

3.  Immunosuppression in man: suppression by macrophages can be mediated by interactions with regulatory T cells.

Authors:  J D Stobo
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

4.  Precipitins to Candida albicans in chronic mucocutaneous candidiasis studied by crossed immunoelectrophoresis with intermediate gel. Correlation with clinical and immunological findings.

Authors:  N H Axelsen; C H Kirkpatrick; R H Buckley
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

5.  Immune abnormalities associated with chronic mucocutaneous candidiasis.

Authors:  H Valdimarsson; J M Higgs; R S Wells; M Yamamura; J R Hobbs; P J Holt
Journal:  Cell Immunol       Date:  1973-03       Impact factor: 4.868

6.  Human mannosidosis--the enzyme defect.

Authors:  M Carroll; N Dance; P K Masson; D Robinson; B G Winchester
Journal:  Biochem Biophys Res Commun       Date:  1972-10-17       Impact factor: 3.575

Review 7.  Chronic mucocutaneous candidosis: a review.

Authors:  I K Aronson; K Soltani
Journal:  Mycopathologia       Date:  1976-12-10       Impact factor: 2.574

Review 8.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.

Authors:  J E Edwards; R I Lehrer; E R Stiehm; T J Fischer; L S Young
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

9.  Specific inhibition of in vitro Candida-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis.

Authors:  A Fischer; J J Ballet; C Griscelli
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

10.  Mannosidosis: clinical, morphologic, immunologic, and biochemical studies.

Authors:  R J Desnick; H L Sharp; G A Grabowski; R D Brunning; P G Quie; J H Sung; R J Gorlin; J U Ikonne
Journal:  Pediatr Res       Date:  1976-12       Impact factor: 3.756

View more
  14 in total

1.  Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.

Authors:  J E Domer; R E Garner; R N Befidi-Mengue
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

Review 2.  Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis.

Authors:  Anne Puel; Sophie Cypowyj; László Maródi; Laurent Abel; Capucine Picard; Jean-Laurent Casanova
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-12

3.  Intermittent ketoconazole therapy of chronic mucocutaneous candidiasis in childhood.

Authors:  S Fanconi; R Seger; P Joller; C Issler; G Schär
Journal:  Eur J Pediatr       Date:  1982-11       Impact factor: 3.183

4.  Enhancement of non-Candida antibody responses by Candida albicans cell wall glycoprotein.

Authors:  J E Domer; K L Elkins; D L Ennist; P W Stashak; R E Garner; P J Baker
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 5.  Candida mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action.

Authors:  R D Nelson; N Shibata; R P Podzorski; M J Herron
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 6.  Cutaneous defenses against dermatophytes and yeasts.

Authors:  D K Wagner; P G Sohnle
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Structural identification of an epitope of antigenic factor 5 in mannans of Candida albicans NIH B-792 (serotype B) and J-1012 (serotype A) as beta-1,2-linked oligomannosyl residues.

Authors:  N Shibata; M Arai; E Haga; T Kikuchi; M Najima; T Satoh; H Kobayashi; S Suzuki
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

8.  Immunological observations before and after successful treatment of chronic mucocutaneous candidiasis with ketoconazole and transfer factor.

Authors:  L Corbeel; J L Ceuppens; G Van den Berghe; H Claeys; M Casteels-Van Daele
Journal:  Eur J Pediatr       Date:  1984-11       Impact factor: 3.183

9.  Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein.

Authors:  E W Carrow; J E Domer
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

10.  Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

Authors:  J E Domer; L G Human; G B Andersen; J A Rudbach; G L Asherson
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.